Index trend and stocks in action on September 04, 2020
Index trend and stocks in action on September 04, 2020

Index trend and stocks in action on September 04, 2020

Karan Dsij Article rating: 4.9

After the formation of a bearish engulfing bar on Monday, Nifty for the third straight day traded within the high-low range of the bearish engulfing bar on Thursday. The price action of the day formed a bearish candle and at the same time, it failed to pierce 50 per cent range of the bearish engulfing bar.

Fear to rule on D-Street
Fear to rule on D-Street

Fear to rule on D-Street

Karan Dsij Article rating: 5.0

The sharp sell-off seen on Wall Street overnight is definitely making way for fear on D-Street. This is quite evident from the severe decline seen in SGX Nifty as it has tumbled 118 points and trading at the 11,425 mark.

Vodafone Idea surges 26 per cent on Amazon & Verizon investment talks
Vodafone Idea surges 26 per cent on Amazon & Verizon investment talks

Vodafone Idea surges 26 per cent on Amazon & Verizon investment talks

Anthony Fernandes Article rating: 4.6

The shares of Vodafone Idea climbed by more than 26 per cent during Thursday's trade amid reports suggesting that the retailer Amazon and the wireless carrier Verizon Communications were looking to invest over US$ 4 billion for a stake in the telecom operator. 

Dr Reddy's Laboratories launches generic Concerta in US market
Dr Reddy's Laboratories launches generic Concerta in US market

Dr Reddy's Laboratories launches generic Concerta in US market

Anthony Fernandes Article rating: 4.2

The shares of Dr Reddy’s Laboratories were trading up by 2 per cent on Thursday after the pharma major announced the launch of Methylphenidate Hydrochloride extended-release tablets USP, 18 mg, 27 mg, 36 mg, and 54 mg, a therapeutic equivalent generic version of Concerta in the US market. 

Strides Pharma receives USFDA approval for Prednisone tablets
Strides Pharma receives USFDA approval for Prednisone tablets

Strides Pharma receives USFDA approval for Prednisone tablets

Rishikesh Gaikwad Article rating: 5.0

Strides Pharma Science Limited (Strides) announced on Thursday that its step-down wholly-owned subsidiary, Strides Pharma Global Pte Limited (Singapore) has received approval for Prednisone tablets USP, 1 mg from United States Food & Drug Administration (USFDA). The product is a generic version of Meticorten tablets, 1 mg of Schering Corporation.

Tata Power bags contract from Ministry of Defence worth Rs 490 crore
Tata Power bags contract from Ministry of Defence worth Rs 490 crore

Tata Power bags contract from Ministry of Defence worth Rs 490 crore

Apurva Joshi Article rating: 5.0

Tata Power Limited’s strategic engineering division (SED) has signed the Pinaka 3 contract with the Ministry of Defence, Government of India. Pinaka multi-barrel launcher rocket system is an all-weather indirect fire artillery rocket system.

Sensex, Nifty volatile; trending stock Vodafone Idea zooms 30 per cent, Page Industries dips 3 per cent
Sensex, Nifty volatile; trending stock Vodafone Idea zooms 30 per cent, Page Industries dips 3 per cent

Sensex, Nifty volatile; trending stock Vodafone Idea zooms 30 per cent, Page Industries dips 3 per cent

Geyatee Deshpande Article rating: 4.9

On Thursday, Sensex ended at 38,990.94 levels after declining by 95.09 points or 0.24 per cent. Nifty closed flat with a positive bias at 11,535.75 levels, up by a mere 0.01 per cent or 0.75 points. The domestic markets fluctuated between minor gains and losses throughout the trading session on Thursday. While India VIX dropped by nearly 3 per cent to 20.53 levels. 

RSS
First24362437243824392441244324442445Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR